Comprehensive Income (Loss), Net of Tax, Attributable to Parent of Achilles Therapeutics plc from 31 Dec 2019 to 30 Jun 2024

Taxonomy & unit
us-gaap: USD
Description
Amount after tax of increase (decrease) in equity from transactions and other events and circumstances from net income and other comprehensive income, attributable to parent entity. Excludes changes in equity resulting from investments by owners and distributions to owners.
Summary
Achilles Therapeutics plc quarterly and annual Comprehensive Income (Loss), Net of Tax, Attributable to Parent in USD history and change rate from 31 Dec 2019 to 30 Jun 2024.
  • Achilles Therapeutics plc Comprehensive Income (Loss), Net of Tax, Attributable to Parent for the quarter ending 30 Jun 2024 was $16,185,000, a 24% decline year-over-year.
  • Achilles Therapeutics plc annual Comprehensive Income (Loss), Net of Tax, Attributable to Parent for 2023 was $61,041,000, a 39% increase from 2022.
  • Achilles Therapeutics plc annual Comprehensive Income (Loss), Net of Tax, Attributable to Parent for 2022 was $99,507,000, a 49% decline from 2021.
  • Achilles Therapeutics plc annual Comprehensive Income (Loss), Net of Tax, Attributable to Parent for 2021 was $66,785,000, a 130% decline from 2020.
Source SEC data
View on sec.gov
Comprehensive Income (Loss), Net of Tax, Attributable to Parent, Quarterly (USD)
Comprehensive Income (Loss), Net of Tax, Attributable to Parent, YoY Quarterly Change (%)
Comprehensive Income (Loss), Net of Tax, Attributable to Parent, Annual (USD)
Comprehensive Income (Loss), Net of Tax, Attributable to Parent, YoY Annual Change (%)

Achilles Therapeutics plc Quarterly Comprehensive Income (Loss), Net of Tax, Attributable to Parent (USD)

Period TTM Value Value YoY Chg Change % Start Date End Date Report Filed Fiscal Year Fiscal Period
Q2 2024 $16,185,000 -$3,156,000 -24% 01 Apr 2024 30 Jun 2024 6-K 14 Aug 2024 2024 Q2
Q2 2023 $13,029,000 +$23,562,000 +64% 01 Apr 2023 30 Jun 2023 6-K 14 Aug 2024 2024 Q2
Q2 2022 $36,591,000 01 Apr 2022 30 Jun 2022 6-K 04 Aug 2023

Achilles Therapeutics plc Annual Comprehensive Income (Loss), Net of Tax, Attributable to Parent (USD)

Period Value YoY Chg Change % Start Date End Date Report Filed Fiscal Year Fiscal Period
2023 $61,041,000 +$38,466,000 +39% 01 Jan 2023 31 Dec 2023 20-F 04 Apr 2024 2023 FY
2022 $99,507,000 -$32,722,000 -49% 01 Jan 2022 31 Dec 2022 20-F 04 Apr 2024 2023 FY
2021 $66,785,000 -$37,799,000 -130% 01 Jan 2021 31 Dec 2021 20-F 04 Apr 2024 2023 FY
2020 $28,986,000 -$23,500,000 -428% 01 Jan 2020 31 Dec 2020 20-F 07 Mar 2023 2022 FY
2019 $5,486,000 01 Jan 2019 31 Dec 2019 20-F 01 Mar 2022 2021 FY
* An asterisk sign (*) next to the value indicates that the value is likely invalid.